MP 102
Alternative Names: MP-102Latest Information Update: 19 Jan 2016
At a glance
- Originator Marathon Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Infantile spasms
Most Recent Events
- 19 Jan 2016 Discontinued - Phase-III for Infantile spasms (In infants) in USA (unspecified route)